MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (TSV:TLT)

0.2250 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 114,673
Open 0.2300
Bid (Size) 0.2250 (40)
Ask (Size) 0.2300 (70)
Prev. Close 0.2250
Today's Range 0.2200 - 0.2300
52wk Range 0.1450 - 0.4100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the... 
Via Newsfile

Performance

YTD
+25.0%
+25.0%
1 Month
-29.7%
-29.7%
3 Month
-22.4%
-22.4%
6 Month
+45.2%
+45.2%
1 Year
+12.5%
+12.5%

More News

Read More
News headline image
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Via Newsfile
News headline image
Theralase(R) Closes $CAN 2.66 Million Financing
Via Newsfile
News headline image
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Via Newsfile
News headline image
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Via Newsfile
News headline image
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Via Newsfile
News headline image
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress ↗
Via Newsfile
News headline image
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Via Newsfile
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via Newsfile
News headline image
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Via Newsfile
News headline image
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Via Newsfile
News headline image
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Via Newsfile
News headline image
Theralase(R) Investor Conference Call Reminder
Via Newsfile
News headline image
Theralase(R) Releases 3Q2025 Financial Statements
Via Newsfile
News headline image
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Via Newsfile
News headline image
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Via Newsfile
Topics Derivatives
News headline image
Theralase(R) Extends Warrants
Via Newsfile
News headline image
Theralase(R) Releases 2Q2025 Financial Statements
Via Newsfile
News headline image
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase(R) Extends Warrants
Via Newsfile
News headline image
Theralase(R) Closes Non-Brokered Private Placement
Via Newsfile
News headline image
Theralase Completes Annual General and Special Meeting
Via Newsfile

Frequently Asked Questions

Is Theralase Technologies Inc publicly traded?
Yes, Theralase Technologies Inc is publicly traded.
What exchange does Theralase Technologies Inc trade on?
Theralase Technologies Inc trades on the Toronto Venture Stock Exchange
What is the ticker symbol for Theralase Technologies Inc?
The ticker symbol for Theralase Technologies Inc is TLT on the Toronto Venture Stock Exchange
What is the current price of Theralase Technologies Inc?
The current price of Theralase Technologies Inc is 0.2250
When was Theralase Technologies Inc last traded?
The last trade of Theralase Technologies Inc was at 05/29/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story